Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Dali
Mandar V. Dali, New Brunswick, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20080234366 | PHARMACEUTICAL FORMULATION CONTAINING AN SGLT2 INHIBITOR - Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate | 09-25-2008 |
| 20110064801 | Pharmaceutical Formulations Containing an SGLT2 Inhibitor - Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate | 03-17-2011 |
Mandar V. Dali, Bridgewater, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20090186857 | Combretastatin A-4 Phosphate Prodrug Mono- and Di- Organic Amine Salts, Mono- and Di- Amino Acid Salts, and Mono- and Di- Amino Acid Ester Salts - Provided herein are novel and useful combretastatin A-4 prodrug salts that increase the solubility of combretastatin A-4, readily regenerate combretastatin A-4 in vivo under normal physiological conditions, and which produce physiologically tolerable products as a result of the regeneration of combretastatin A-4. | 07-23-2009 |
Manisha M. Dali, Bridgewater, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20090186857 | Combretastatin A-4 Phosphate Prodrug Mono- and Di- Organic Amine Salts, Mono- and Di- Amino Acid Salts, and Mono- and Di- Amino Acid Ester Salts - Provided herein are novel and useful combretastatin A-4 prodrug salts that increase the solubility of combretastatin A-4, readily regenerate combretastatin A-4 in vivo under normal physiological conditions, and which produce physiologically tolerable products as a result of the regeneration of combretastatin A-4. | 07-23-2009 |
| 20100166774 | Stable Protein Formulations - The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for example, routes such as intravenous (IV) and subcutaneous (SC) for treating immune system diseases and tolerance induction. | 07-01-2010 |
Vishal Dali, Richardson, TX US
| Patent application number | Description | Published |
|---|---|---|
| 20110060693 | Vending Machine for Large Product Containers - The present invention provides machines, methods and apparatus for automatically vending, damping, delivering and returning large heavy product containers such as 5-gallon water bottles. In some embodiments, damping methods and apparatus are provided to gently transfer large heavy product containers from one level to another inside a vending machine. In some embodiments, methods and apparatus including adjustable support rails are provided for handling different sized large heavy product containers inside a vending machine. In some embodiments, delivery methods and apparatus are provided for use with large heavy product containers. In some embodiments, methods and apparatus for returning large product containers are provided. Some or all of these features may be provided in a single vending machine, or in multiple machines, and multiple features or machines may be controlled by a single computer processor. | 03-10-2011 |
| 20110071772 | Methods for Monitoring and Managing Delivery of Syrup in Bag-In-Box Systems - The present invention includes systems, methods and apparatus for detecting whether an acceptable mixture of fluid and water has been delivered by a vending machine. Embodiments of the invention utilize one or more second flow meters located downstream of a mix manifold. The additional flow meter allows the controller of the delivery system or vending machine to monitor and compare the volume of water to the volume of the final mix in order to determine whether an appropriate volume of syrup has or has not been mixed in the dispensed beverage. | 03-24-2011 |